Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Stock Short Interest Falls 85.3%

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the recipient of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totaling 268,742 shares, a decrease of 85.3% from the August 31st total of 1,828,008 shares. Based on an average daily volume of 1,305,660 shares, the short-interest ratio is currently 0.2 days. Currently, 0.2% of the shares of the stock are short sold.

Analysts Set New Price Targets

Separately, Loop Capital set a $1.00 price target on Xtant Medical in a research note on Wednesday, September 2nd. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $1.00.

Xtant Medical Price Performance

Xtant Medical stock traded down $0.01 during mid-day trading on Friday, reaching $0.37. The company had a trading volume of 78,675 shares, compared to its average volume of 682,978. Xtant Medical has a fifty-two week low of $0.27 and a fifty-two week high of $0.95. The company has a current ratio of 2.16, a quick ratio of 1.05 and a debt-to-equity ratio of 0.18. The company has a market cap of $52.05 million, a P/E ratio of -4.64 and a beta of -0.15. The business has a fifty day simple moving average of $0.38 and a 200 day simple moving average of $0.45.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its quarterly earnings results on Tuesday, August 11th. The medical device company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.05). Xtant Medical had a negative return on equity of 23.45% and a negative net margin of 10.17%.The company had revenue of $23.03 million for the quarter, compared to analyst estimates of $24.88 million.

Hedge Funds Weigh In On Xtant Medical

A number of institutional investors and hedge funds have recently bought and sold shares of XTNT. AWM Investment Company Inc. acquired a new stake in shares of Xtant Medical during the second quarter valued at about $2,516,000. Renaissance Technologies LLC increased its stake in shares of Xtant Medical by 7.3% in the first quarter. Renaissance Technologies LLC now owns 987,410 shares of the medical device company’s stock valued at $551,000 after buying an additional 67,550 shares during the period. Tradition Wealth Management LLC bought a new position in Xtant Medical in the 4th quarter valued at approximately $79,000. Finally, Hillsdale Investment Management Inc. acquired a new stake in Xtant Medical during the 4th quarter worth approximately $284,000. Institutional investors and hedge funds own 69.33% of the company’s stock.

About Xtant Medical

Xtant Medical Holdings, Inc is a medical technology company focused on developing, manufacturing and marketing surgical products for spinal and orthopedic procedures. The company’s portfolio includes biologic products designed to support bone growth and tissue repair, as well as spinal implants and related surgical instruments.

Its products are used by surgeons and hospitals in procedures involving spinal fusion, reconstruction and other orthopedic applications. Xtant’s biologics portfolio includes allograft and other regenerative solutions, while its hardware offerings include implants and instrumentation intended to support spinal stabilization and correction.

Xtant Medical is headquartered in Belgrade, Montana, and primarily serves the U.S.